2018年两位免疫学家Tasuku Honjo和James P. Allison教授因发现 “免疫检查点抑制剂(Immune checkpoint inhibitors,ICI)治疗癌症”而获得诺贝尔生理学或医学奖,将肿瘤免疫治疗推向高潮。 免疫检查点抑制剂作为肿瘤免疫治疗中最具代表性的治疗方法,毫无疑问是肿瘤免疫治疗中...
免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)疗法为肿瘤患者带来新的富有前景的治疗策略。常见的免疫检查点包括PD-1、CTLA-4、TIGIT、TIM3和LAG-3等。研究发现ICIs联合治疗相比于任何单药治疗具有更好的治疗效果(详见BioArt报道:...
2018年两位免疫学家Tasuku Honjo和James P. Allison教授因发现 “免疫检查点抑制剂(Immune checkpoint inhibitors,ICI)治疗癌症”而获得诺贝尔生理学或医学奖,将肿瘤免疫治疗推向高潮。 免疫检查点抑制剂作为肿瘤免疫治疗中最具代表性的治疗方法,毫无疑问是肿瘤免疫治疗中的皇冠。而从目前格局来看,PD-1/PD-L1抑制剂可以...
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis. Exp Hematol Oncol. 2019;8:26. [5]Li T, Niu M, Zhou J, et al. The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling. Cell Commun Signal 22, 179 (2024);22:179....
Cancer immunotherapies, represented by immune checkpoint inhibitors (ICIs), have reshaped the treatment paradigm for both advanced non-small cell lung cancer and small cell lung cancer. Programmed death receptor-1/programmed death receptor ligand-1 (PD-1
详细报告目录内容或者申请报告框架样本参考可点击:https://www.yhresearch.cn/reports/2062569/ctla-4-inhibitors-for-cervical-cancer 1 市场综述 1.1 治疗宫颈癌的CTLA-4抑制剂定义及分类 1.2 全球治疗宫颈癌的CTLA-4抑制剂行业市场规模及预测 1.2.1 按收入计,全球治疗宫颈癌的CTLA-4抑制剂市场规模,2019-2030 ...
17 款 PD-1/PD-L1/CTLA-4 免疫抑制剂，一图讲全！免疫检查点抑制剂（immune checkpoint inhibitors，ICIs）为代表的免疫疗法通过激活患者自身 T 淋巴细胞的抗肿瘤免疫功能，发挥杀灭肿瘤细胞的作用，在临床上已被广泛使用。ICIs 作为针对细胞毒性 T 淋巴细胞相关抗原 4（cytotoxic T-lymphocyte-associated protein 4...
免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)为代表的免疫疗法通过激活患者自身 T 淋巴细胞的抗肿瘤免疫功能,发挥杀灭肿瘤细胞的作用,在临床上已被广泛使用。 ICIs 作为针对细胞毒性 T 淋巴细胞相关抗原 4(cytotoxic T-lymphocyte-associated protein 4,CTLA-4)和程序性死亡蛋白 1(programmed death 1,PD-1)...
SUN-332 Autoimmune Endocrinopathies Associated with CTLA-4 Inhibitors: A Meta-Analysisdoi:10.1210/js.2019-SUN-332Objective: To assess the risks of immune-related endocrinopathies associated with anticytotoxic T-lymphocyte-associated antigen 4 (CTLA4) therapies Methods: Participants who were assigned ...
[1] Ok CY, Young KH. Checkpoint inhibitors in hematological malignancies. J Hematol Oncol. 2017;10:1–16.[2]. Quandt D, Hoff H, Rudolph M, Fillatreau S, Brunner-Weinzierl MC. A new role of CTLA-4 on B cells in thymus-dependent immune responses in vivo. J Immunol. 2007;179:7316...